United Therapeutics Co. (NASDAQ:UTHR) Shares Acquired by NewEdge Advisors LLC

NewEdge Advisors LLC grew its position in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 124.6% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 3,027 shares of the biotechnology company's stock after acquiring an additional 1,679 shares during the quarter. NewEdge Advisors LLC's holdings in United Therapeutics were worth $1,068,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Newbridge Financial Services Group Inc. acquired a new position in shares of United Therapeutics in the fourth quarter valued at approximately $25,000. Millstone Evans Group LLC acquired a new stake in shares of United Therapeutics in the 4th quarter worth $67,000. MassMutual Private Wealth & Trust FSB boosted its holdings in shares of United Therapeutics by 31.9% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biotechnology company's stock valued at $85,000 after acquiring an additional 58 shares in the last quarter. Anchor Investment Management LLC increased its stake in shares of United Therapeutics by 12.0% during the fourth quarter. Anchor Investment Management LLC now owns 280 shares of the biotechnology company's stock worth $99,000 after acquiring an additional 30 shares during the period. Finally, Jones Financial Companies Lllp raised its holdings in United Therapeutics by 678.9% during the fourth quarter. Jones Financial Companies Lllp now owns 296 shares of the biotechnology company's stock worth $104,000 after purchasing an additional 258 shares in the last quarter. 94.08% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on the company. HC Wainwright reiterated a "buy" rating and set a $425.00 target price on shares of United Therapeutics in a research report on Thursday, February 27th. Bank of America upgraded shares of United Therapeutics from an "underperform" rating to a "neutral" rating and set a $314.00 target price on the stock in a research report on Monday, April 21st. UBS Group upped their price target on United Therapeutics from $415.00 to $475.00 and gave the stock a "buy" rating in a report on Wednesday, January 8th. JPMorgan Chase & Co. reduced their price objective on United Therapeutics from $357.00 to $355.00 and set an "overweight" rating for the company in a report on Monday, April 21st. Finally, Wells Fargo & Company reissued an "equal weight" rating and issued a $314.00 target price (down previously from $395.00) on shares of United Therapeutics in a report on Friday. Four investment analysts have rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $390.17.

United Therapeutics Stock Performance

United Therapeutics stock traded up $5.66 during midday trading on Monday, reaching $297.04. 410,281 shares of the company were exchanged, compared to its average volume of 447,897. The company has a market capitalization of $13.34 billion, a price-to-earnings ratio of 13.05, a P/E/G ratio of 0.97 and a beta of 0.63. The firm's 50-day simple moving average is $308.67 and its 200-day simple moving average is $346.42. United Therapeutics Co. has a 1 year low of $233.31 and a 1 year high of $417.82.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its quarterly earnings data on Wednesday, February 26th. The biotechnology company reported $6.19 earnings per share for the quarter, beating analysts' consensus estimates of $6.10 by $0.09. The business had revenue of $735.90 million during the quarter, compared to analyst estimates of $734.74 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. During the same quarter in the previous year, the business posted $4.36 earnings per share. On average, analysts forecast that United Therapeutics Co. will post 24.48 EPS for the current fiscal year.

Insider Transactions at United Therapeutics

In related news, COO Michael Benkowitz sold 10,000 shares of United Therapeutics stock in a transaction on Monday, February 10th. The stock was sold at an average price of $348.06, for a total value of $3,480,600.00. Following the transaction, the chief operating officer now owns 2,577 shares in the company, valued at approximately $896,950.62. This trade represents a 79.51 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Paul A. Mahon sold 11,000 shares of the company's stock in a transaction dated Thursday, April 3rd. The stock was sold at an average price of $306.18, for a total value of $3,367,980.00. Following the sale, the executive vice president now owns 36,781 shares of the company's stock, valued at $11,261,606.58. This represents a 23.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 74,500 shares of company stock worth $24,472,050 over the last quarter. 11.90% of the stock is currently owned by insiders.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.